On July 6, Novo Nordisk fell 3.05% in regular trading, trading at $48.80/share, with Turnover of $81.78 million.
Within the Pharmacy sector where Novo Nordisk belongs, the overall sector performance was weak. Among individual stocks, Eli Lilly down 2.2%, Johnson & Johnson down 2.64%, Pfizer down 2.18%, Merck down 2.04%, AstraZeneca PLC down 4.14%.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)